Company intelligence / Profile preview
Hengrui Therapeutics
Lianyungang, Jiangsu, Chinahengrui.com ↗
- Ownership
- Public · 600276
- Employees
- ~24500
- Development stage
- Other
01
Overview
Hengrui has achieved significant clinical milestones including positive global Phase 3 results with camrelizumab plus rivoceranib for advanced hepatocellular carcinoma. The company has over a dozen new molecular entities marketed in China and a robust pipeline spanning oncology and metabolic disease with more than ninety innovative drug candidates under development.
- Therapeutic areas
- Metabolic DisordersImmunologyOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesMonoclonal antibodies (mAbs)Protein engineering platforms (including mRNA technology)
- Industry
- Pharma
02
Drug pipeline
194 assets193 more assets in the full pipeline.
03
Financials
- Market cap
- $48.2B
- Total revenue
- $4.7B
- Enterprise value
- $41.8B
Beyond the preview
Go deeper on Hengrui Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hengrui Therapeutics.